Heparin Prophylaxis in Hospitalized Pediatric Patients
Heparin prophylaxis is NOT routinely necessary for most hospitalized pediatric patients, but should be strongly considered for adolescents (≥13 years) with multiple VTE risk factors and no bleeding contraindications. 1
Risk-Stratified Approach to VTE Prophylaxis
Basic Prophylaxis (ALL hospitalized children without contraindications)
- Ensure adequate hydration
- Early mobilization when possible
- Early removal of central venous catheters when no longer needed
- Avoid prolonged immobility 1
Age-Based Thresholds for Pharmacologic Prophylaxis
Children <13 years: Pharmacologic prophylaxis is generally NOT recommended for routine hospitalization 1. The evidence shows that most pediatric VTE occurs in younger children (41% in infants <1 year) 2, yet current guidelines do not support routine prophylaxis in this age group due to insufficient evidence of benefit versus bleeding risk.
Adolescents ≥13 years with multiple risk factors: Pharmacologic prophylaxis IS recommended when multiple thrombotic risk factors are present and no bleeding risk exists 1.
Key VTE Risk Factors to Assess 1, 3
Count the following risk factors present:
- Central venous catheter (most common - present in 82% of pediatric VTE cases) 2
- Mechanical ventilation
- Complete immobility (Braden Q Mobility Score = 1)
- Prolonged hospitalization (anticipated >3 days)
- Obesity (BMI >95th percentile)
- Active malignancy
- Age >12 years or pubertal/post-pubertal status
- Cardiac disease with venous stasis
- Previous VTE history
- Known thrombophilia
- Oral contraceptive use
- Major trauma (especially with injury severity score >25)
- Inflammatory conditions (lupus, IBD, nephrotic syndrome)
Decision Rule: If ≥3 risk factors present in any age OR ≥1 risk factor in adolescent ≥13 years → consider pharmacologic prophylaxis 3
Recommended Prophylaxis Regimens
Mechanical Prophylaxis
- Intermittent pneumatic compression devices or antiembolism stockings for at-risk adolescents ≥13 years 1
- Consider for trauma patients ≥15 years (or younger post-pubertal children with injury severity score >25) 1
- Important caveat: Graduated compression stockings showed no benefit in adult studies 4, so pneumatic compression devices are preferred when mechanical prophylaxis is used
Pharmacologic Prophylaxis
First-line: Low Molecular Weight Heparin (LMWH) 5
- Preferred over unfractionated heparin due to safety, ease of use, and predictable pharmacology
- Target anti-Xa level: 0.2 to <0.5 U/mL (4 hours post-dose) 3
- Subcutaneous administration twice daily
- Can be continued at platelet counts >20 × 10⁹/L 5
- Withhold if platelets <20 × 10⁹/L 5
Alternative: Unfractionated Heparin (UFH) 3, 6
- Use when LMWH contraindicated (severe renal impairment, need for rapid reversibility)
- Continuous IV infusion targeting anti-Xa 0.1 to <0.35 U/mL
- Pediatric dosing 7, 6:
- Initial: 50 units/kg IV bolus
- Maintenance: 20 units/kg/hour (children >1 year) or 28 units/kg/hour (infants <1 year)
- Monitor aPTT every 4 hours initially, targeting 1.5-2× normal (60-85 seconds)
Recent data shows: Standard weight-based dosing (89.3 units/kg subcutaneously) resulted in 11% VTE rate and 24% bleeding rate in PICU patients 8, suggesting current prophylactic strategies may be suboptimal and require individualized monitoring.
Special High-Risk Situations Requiring Prophylaxis
Pediatric Cancer Patients 5
- All children undergoing major surgery with history of DVT (cancer-related or not): Use LMWH prophylaxis unless contraindicated
- Consider mechanical prophylaxis during hospitalization with immobility
- Add pharmacologic prophylaxis if additional risk factors present (adolescent with obesity or on oral contraceptives)
Cardiac Catheterization 1
- Unfractionated heparin is superior to aspirin or no prophylaxis
- UFH reduced femoral artery thrombosis from 40% to 8%
- Aspirin did NOT significantly reduce thrombosis risk
COVID-19/MIS-C Patients 3
- Prophylaxis recommended if:
- D-dimer >5× upper limit of normal, OR
- ≥1 additional VTE risk factor present
- Use LMWH targeting anti-Xa 0.2 to <0.5 U/mL
Critical Safety Considerations
Monitoring Requirements 7, 6
- Baseline: Platelet count, hemoglobin, coagulation studies
- During therapy:
- Platelet counts regularly (risk of HIT, though rare in children)
- Anti-Xa levels for LMWH (especially in children <2 years who may need higher doses) 9
- aPTT for UFH every 4 hours initially
- Monitor for occult bleeding (stool guaiac)
Contraindications to Pharmacologic Prophylaxis 6
- Active bleeding or high bleeding risk
- Severe thrombocytopenia (<20 × 10⁹/L for prophylactic dosing)
- Recent neurosurgery, spinal procedures, or eye surgery
- Severe uncontrolled hypertension
- Known heparin-induced thrombocytopenia
Age-Specific Warnings 6
- DO NOT use benzyl alcohol-preserved heparin in neonates/infants - risk of fatal "gasping syndrome"
- Use preservative-free formulations only in this age group
- Infants <1 year require higher weight-based doses to achieve therapeutic levels 9
Common Pitfalls to Avoid
Assuming adult guidelines apply to all children: Only adolescents ≥13 years have evidence supporting routine prophylaxis 1
Overlooking central line as major risk factor: Present in 82% of pediatric VTE cases 2, yet often not counted as sufficient indication alone in younger children
Using wrong heparin concentration: Fatal errors have occurred confusing 10,000 units/mL vials with catheter lock flush concentrations 6
Inadequate monitoring in young children: Children <2 years and those with oncologic/nephrologic disease often need dose adjustments to achieve target anti-Xa levels 9
Applying prophylaxis too broadly: Current guidelines would have recommended prophylaxis in only 16-21% of children who actually developed VTE 2, but this doesn't justify universal prophylaxis given bleeding risks
Bottom Line Algorithm
Step 1: Count VTE risk factors (see list above)
Step 2: Assess age and bleeding risk
Step 3: Apply decision rule:
- Age <13 years + <3 risk factors: Basic prophylaxis only
- Age <13 years + ≥3 risk factors: Consider mechanical ± pharmacologic prophylaxis
- Age ≥13 years + ≥1 risk factor + no bleeding risk: Mechanical + pharmacologic prophylaxis recommended
- High-risk scenarios (cancer surgery with prior VTE, cardiac catheterization, COVID-19 with elevated D-dimer): Pharmacologic prophylaxis regardless of age
Step 4: If pharmacologic prophylaxis indicated, use LMWH (preservative-free in infants) with anti-Xa monitoring, especially in children <2 years